Halozyme, a San Diego-based biotech, said Monday that its lead drug, for pancreatic cancer, had failed to extend the lives of patients in a clinical trial.

The company is discontinuing all of its studies of the drug, PEGPH20. It will refocus entirely on its already lucrative drug delivery technology, which is being used by drug giants including Roche (RHHBY), Johnson & Johnson (JNJ), and Bristol-Myers Squibb to turn medicines that must be given intravenously over a period of hours into shots that patients can receive in minutes.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.